Cargando…
The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112613/ https://www.ncbi.nlm.nih.gov/pubmed/31972212 http://dx.doi.org/10.1016/j.jinf.2019.12.022 |
_version_ | 1783513507177693184 |
---|---|
author | Piñana, JoséLuis Montoro, Juan Aznar, Carla Lorenzo, Ignacio Gómez, María Dolores Guerreiro, Manuel Carretero, Carlos González-Barberá, Eva María Balaguer-Roselló, Aitana Sanz, Rosa Salavert, Miguel Navarro, David Sanz, Miguel A. Sanz, Guillermo Sanz, Jaime |
author_facet | Piñana, JoséLuis Montoro, Juan Aznar, Carla Lorenzo, Ignacio Gómez, María Dolores Guerreiro, Manuel Carretero, Carlos González-Barberá, Eva María Balaguer-Roselló, Aitana Sanz, Rosa Salavert, Miguel Navarro, David Sanz, Miguel A. Sanz, Guillermo Sanz, Jaime |
author_sort | Piñana, JoséLuis |
collection | PubMed |
description | BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT recipients with CARV infections. The retrospective cohort included 63 allo-HCT recipients with 108 CARV infections from January 2013 to April 2016 who were screened and managed following standard clinical practice based on influenza and respiratory syncytial virus rapid antigen detection methods. The prospective cohort was comprised of 144 consecutive recipients with 297 CARV episodes included in a prospective interventional clinical surveillance program (ProClinCarvSur-P) based on syndromic multiplex PCR as first-line test from May 2016 to December 2018 at a single transplant center. RESULTS: CARV infections in the retrospective cohort showed more severe clinical features at the time of diagnosis compared to the prospective cohort (fever 83% vs. 57%, hospital admission 69% vs. 28% and lower respiratory tract 58% vs. 31%, respectively, p ≤ 0.002 for all comparisons). Antiviral therapy was more commonly prescribed in the prospective cohort (69 vs. 43 treated CARV episodes), particularly at the upper respiratory tract disease stage (34 vs. 12 treated CARV episodes). Three-month all-cause mortality was significantly higher in the retrospective cohort (n = 23, 37% vs. n = 10, 7%, p < 0.0001). Multivariate logistic regression analysis showed that recipients included in ProClinCarvSur-P had lower mortality rate [odds ratio 0.31, 95% confidence interval 0.12–0.7, p = 0.01]. CONCLUSION: This study report on outcome differences when reporting retrospective vs. prospective CARV infections after allo-HCT. Recipients included in a ProClinCarvSur-P had lower mortality. |
format | Online Article Text |
id | pubmed-7112613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The British Infection Association. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71126132020-04-02 The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation Piñana, JoséLuis Montoro, Juan Aznar, Carla Lorenzo, Ignacio Gómez, María Dolores Guerreiro, Manuel Carretero, Carlos González-Barberá, Eva María Balaguer-Roselló, Aitana Sanz, Rosa Salavert, Miguel Navarro, David Sanz, Miguel A. Sanz, Guillermo Sanz, Jaime J Infect Article BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT recipients with CARV infections. The retrospective cohort included 63 allo-HCT recipients with 108 CARV infections from January 2013 to April 2016 who were screened and managed following standard clinical practice based on influenza and respiratory syncytial virus rapid antigen detection methods. The prospective cohort was comprised of 144 consecutive recipients with 297 CARV episodes included in a prospective interventional clinical surveillance program (ProClinCarvSur-P) based on syndromic multiplex PCR as first-line test from May 2016 to December 2018 at a single transplant center. RESULTS: CARV infections in the retrospective cohort showed more severe clinical features at the time of diagnosis compared to the prospective cohort (fever 83% vs. 57%, hospital admission 69% vs. 28% and lower respiratory tract 58% vs. 31%, respectively, p ≤ 0.002 for all comparisons). Antiviral therapy was more commonly prescribed in the prospective cohort (69 vs. 43 treated CARV episodes), particularly at the upper respiratory tract disease stage (34 vs. 12 treated CARV episodes). Three-month all-cause mortality was significantly higher in the retrospective cohort (n = 23, 37% vs. n = 10, 7%, p < 0.0001). Multivariate logistic regression analysis showed that recipients included in ProClinCarvSur-P had lower mortality rate [odds ratio 0.31, 95% confidence interval 0.12–0.7, p = 0.01]. CONCLUSION: This study report on outcome differences when reporting retrospective vs. prospective CARV infections after allo-HCT. Recipients included in a ProClinCarvSur-P had lower mortality. The British Infection Association. Published by Elsevier Ltd. 2020-03 2020-01-20 /pmc/articles/PMC7112613/ /pubmed/31972212 http://dx.doi.org/10.1016/j.jinf.2019.12.022 Text en © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Piñana, JoséLuis Montoro, Juan Aznar, Carla Lorenzo, Ignacio Gómez, María Dolores Guerreiro, Manuel Carretero, Carlos González-Barberá, Eva María Balaguer-Roselló, Aitana Sanz, Rosa Salavert, Miguel Navarro, David Sanz, Miguel A. Sanz, Guillermo Sanz, Jaime The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
title | The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
title_full | The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
title_fullStr | The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
title_full_unstemmed | The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
title_short | The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
title_sort | clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112613/ https://www.ncbi.nlm.nih.gov/pubmed/31972212 http://dx.doi.org/10.1016/j.jinf.2019.12.022 |
work_keys_str_mv | AT pinanajoseluis theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT montorojuan theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT aznarcarla theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT lorenzoignacio theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT gomezmariadolores theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT guerreiromanuel theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT carreterocarlos theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT gonzalezbarberaevamaria theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT balaguerroselloaitana theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzrosa theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT salavertmiguel theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT navarrodavid theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzmiguela theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzguillermo theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzjaime theclinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT pinanajoseluis clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT montorojuan clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT aznarcarla clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT lorenzoignacio clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT gomezmariadolores clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT guerreiromanuel clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT carreterocarlos clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT gonzalezbarberaevamaria clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT balaguerroselloaitana clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzrosa clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT salavertmiguel clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT navarrodavid clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzmiguela clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzguillermo clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation AT sanzjaime clinicalbenefitofinstitutingaprospectiveclinicalcommunityacquiredrespiratoryvirussurveillanceprograminallogeneichematopoieticstemcelltransplantation |